Roche promotes Foundation Medicine chief to lead its North American diagnostics unit, reinforcing internal talent pipeline
Executive summary: Roche appointed Dan Malarek as President and CEO of Roche Diagnostics North America, with the change taking effect August 1, 2026, while incumbent Brad Moore retires at the end of July. The move reinforces Roche's internal succession planning, integrates Foundation Medicine's oncology diagnostics expertise into its North American diagnostics business, and may influence competitive dynamics in the IVD market.
Who is involved: Roche (parent company), Dan Malarek (incoming President and CEO of Roche Diagnostics North America), Brad Moore (outgoing President and CEO).
Likely next: Dan Malarek assumes the role on August 1, 2026; Brad Moore departs after his final day in July; Roche Diagnostics North America will continue its diagnostic portfolio execution under the new leadership.
Roche has named Dan Malarek, current CEO of Foundation Medicine, as President and CEO of Roche Diagnostics North America, effective August 1, 2026. He succeeds Brad Moore, who will retire at the end of July after nearly a decade with the company. The appointment signals continuity in Roche's diagnostic leadership and brings expertise from its recent Foundation Medicine acquisition to the North American market.
Timeline
- — Roche Appoints Dan Malarek as President and CEO of Roche Diagnostics North America (PR Newswire)
- — The Hanover Announces CEO Succession Plan: John C. Roche to Retire as President and CEO at the End of 2026; Chief Operating Officer Richard W. Lavey Named CEO-Elect (PR Newswire)
- — Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis (GlobeNewswire)
- — Roche receives CE Mark for blood test to identify tuberculosis infection (GlobeNewswire)
- — Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying (Investors.com)
Analysis — what this means
Likely next events
- Dan Malarek assumes role as President and CEO of Roche Diagnostics North America on August 1, 2026.
- Brad Moore retires from Roche Diagnostics North America at the end of July 2026.
Sectors affected
- in vitro diagnostics
- North American healthcare market
Historical parallels
- Roche's CEO succession plan at The Hanover Insurance Group announced July 15, 2026.
- Roche launched the cobas Hepatitis D Virus test on July 14, 2026.
Key entities
Sources
- Roche Appoints Dan Malarek as President and CEO of Roche Diagnostics North America — PR Newswire
- The Hanover Announces CEO Succession Plan: John C. Roche to Retire as President and CEO at the End of 2026; Chief Operating Officer Richard W. Lavey Named CEO-Elect — PR Newswire
- Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis — GlobeNewswire
- Roche receives CE Mark for blood test to identify tuberculosis infection — GlobeNewswire
- Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying — Investors.com